CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Published on:
Feliza Mirasol
Pharmaceutical Technology, The Real Message Behind Commercial mRNA Products, April 2023 eBook, Volume 2023 eBook, Issue 3
Pages: 12–17
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
Nucleic acid-based therapeutics have been stepping up into the spotlight following the deployment of messenger RNA (mRNA) COVID-19 vaccines in 2021 and the rise in clinical development programs for gene therapies. These areas of development may just be the surface of the types of therapeutic applications where nucleic acid-based therapeutics can come into play. Tackling the development challenges of these therapeutics can potentially benefit more expansive areas of unmet medical need, particularly in difficult-to-treat patient populations.
Advertisement
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook
About the author
Feliza Mirasol is science editor for Pharmaceutical Technology.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 12–17
Citation
When referring to this article, please cite it as Mirasol, F. Nucleic Acid-based Therapeutics Are Stepping into the Spotlight. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Related Content:
